Milks Material - BMS

T-Cell Antigen common to all T-cells; (also NK cells)

T-cell Antigen complexed with the alpha and beta chains of the TCR; thymocytes, peripheral T cells

• T-cell Antigent that's a helper/inducer T-Cell Class II MHC coreceptor
• Helper subset of peripheral T cells, single positive medullary thymocytes, and CD4/CD8 double positive thymocytes

• T-cell Antigen that's cytotoxic/suppressor T-cell Class I MHC coreceptor
• cytotoxic subset of peripheral T cells, single positive medullary thymocytes, double positive coritcal thyocytes, and some NK cells

T-cell Antigen and a T-cell receptor; antigen binding (single paratope)

• B-cell antigent that deals with signal transduction; (B-cell co-receptor
• NOT expressed on plasma cells
• marrow pre-B cells and mature B cells

• B-cell antigen characteristic surface antigen of normal and malignant B-cells
• marrow pre-B cells after CD19 and mature B cells
• NOT plasma cells

B-cell antigen that's complement C3b receptor; (B-cell co-receptor); EBV "receptor;" present on mature B cells and follicular dendritic cells

B-cell antigen Fc receptor for IgG

B-cell antigen that's TAPA-1; (B-cell co-receptor)

B-cell antigen (monomeric); antigen binding (2 identical paratopes)

• primarily monocyte/macrophage associated
• granulocytes, monocytes, macrophages; also expressed by hairy cell leukemias

NK cells and granulocytes

NK cels and subset of T cells

• Prototype Disorder: anaphylaxis; allergies; bronchial asthma (atopic forms)
• Immune Mechanisms: production of IgE antibody -> immediate release of vasoactive amines and other mediators from mast cells; recruitment of inflammatory cells (late phase reaction)
• Pathologic Lesions: vascular dilation, edema, smooth muscle contraction, mucus production, inflammation

• activate complement
• Prototype Disorder: hemolytic anemia; Goodpasture syndrome
• Immune Mechanism: Production of IgG, IgM -> binds to antigen on target cell/tissue -> phagocytosis or lysis of target cell by activated complement or Fc receptors; recruitment of leukocytes
• Pathologic Lesions: cell lysis; inflammation

• circulating antibdoies binding to circulating antigens
• Prototype Disorder: systemic lupus erythematosus; some forms of glomerulonephritis; serum sickness; Arthus reaction
• Immune Mechanisms: Deposition of antigen-antibody complexes -> complement activation -> recruitment of leukocytes by complement products and Fc receptors -> release of enzymes and other toxic molecules
• Pathologic Lesions: necrotizing vasculitis (fibrinoid necorsis); inflammation

• TH1 cells
• Prototype Disorder: contact dermatitis; multiple sclerosis; type I, diabetes; translpant rejection; tuberculosis
• Immune Mechanism: Activated T lymphocytes -> release of cytokines and macrophage activation; T-cell mediated cytotoxicity
• Pathologic Lesions: Perivascular cellular infiltrates; edema; cell destruction; granuloma formation

• Target Antigen: erythrocyte membrane proteins (Rh blood group antigens, I antigen)
• Mechanisms of Disease: opsonization and phagocytosis of erythrocytes
• Clinicopathologic Manifestations: hemolysis, anemia

• Target Antigen: platelet membrane protiens (gp2b:gp3a integrin)
• Mechanisms of Disease: opsonization and phagocytosis of platelets
• Clinicopathologic Manifestations: bleeding

• Target Antigen: noncollagenous protein in basement membranes of kidney glomeruli and lung alveoli
• Mechanisms of Disease: complement- and Fc receptor- mediated inflammation
• Clinicopathologic Manifestations: nephritis, lung hemorrhage

• Target Antigen: acetylcholine receptor
• Mechanisms of Disease: antibody inhibits acetylcholine binding, down-modulates receptors
• Clincopathologic Manifestations: muscle weakness, paralysis

• Target Antigen: TSH receptor
• Mechanisms of Disease: antibody-mediated stimulation of TSH receptors
• Clinicopathologic Manifestations: hyperthyroidism

• Antigen involved: DNA, nuceloproteins, others
• Clincopathologic Manifestations: nephritis, arthritis, vasculitis

• took awhile to generate antibodies at the damage skin
• Antigen Involved: stretococcal cell wall antigen(s); may be "planted" in glomerular basement membrane
• Clinicopathologic Manifestations: nephritis

• Antigent Involved: various foreign proteins - local where antigens stay
• Clinicopathologic Manifestations: cutaneous vasculitis

monoclonal antibody

species source

human

murine (mouse)

rat

primate

chimeric- mostly human, but some mouse

humanized - ~95% human, remaining mouse

target

viral

immune system

interleukins

circulatory

tumor

• Ligand/Target: CD3 on T-lymphocytes
• Indication: acute graft rejection

• Ligand/Taget: glycoprotein IIb/IIIa receptors on platelets
• Indication: prevent reocclusion of coronary arteries following PTCA

• Ligand/Target: CD20 on B lymphocytes
• Indication: non-Hodkin's lymphoma
• chronic lymphotcyic leukemia
• rheumatoid arthritis
• Wegener's Granulomatosis (WG) and Microscopic Polyangiitis

• Ligand/Target: CD20 on B lymphocytes
• Indication: non-Hodgkin's lymphoma

• Ligand: CD20 on B lymphocytes
• Indication: non-Hodgkin's lymphoma

• Ligand: CD20 on B-lymphocytes
• Indication: chronic lympocytic leukemia

• CD30 on malignant lymphocytes
• Indications: Hodgkin lymphoma
• anaplastic large cell lymphoma (ALCL)

• Ligand: CD52 on leukocytes
• Indication: B-cell chronic lymphocytic leukemia

• Ligand: CTLA-4 on T-lymphocytes
• Indication: malignant melanoma

• Herceptin
• Ligand: Human Epidermal growth factor Receptor (HER2)
• Indication: metastatic breast cancer

• Erbitux
• Ligand: Epidermal Growth Factor Receptor (EGFR-1; HER-1; c-Erb-1)
• Indication: metastatic colorectal carcinoma
• head and neck squamous cell carcinoma

• Ligand: Epidermal Growth Factor Receptor (EGFR-1; HER-1; c-Erb-1)
• Indication: colorectal carcinoma

• Ligand: Vascular Endothelial Growth Factor (VEGF)
• Indication: metastatic colorectal carcinoma
• glioblastoma
• metastatic renal cell carcinoma
• nonsquamous non-small lung cancer

• Ligand: Vascular Endothelial Growth Factor (VEGF)
• Indication: neovascular ("wet") age related macular degeneration (AMD)

• Ligand: binds to alpha-subunit (CD25) of IL-2 receptors
• Indication: immunosuppressant

• Ligand: binds to alpha-subunit (Tac) of IL-2 receptors
• Indication: immunosuppressant

• Ligand: binds to B-lymphocyte stimulator
• Indication: systemic lupus erythematosus

• Ligand: TNF-alpha
• Indication: rheumatoid arthritis
• psoriatic arthritis
• plaque psoriasis
• ankylosing spondylitis
• ulcerative colitis
• Crohn's disease

• Ligand: TNF-alpha
• Indication: rheumatoid arthritis
• juvenile idiopathic arthritis
• psoriatic arthritis
• ankylosing spondylitis
• Crohn's Disease
• plaque psoriasis

• Ligand: TNF-alpha
• Indication: rheumatoid arthritis
• psoriatic arthritis
• ankylosing spondylitis

• Ligand: TNF-alpha
• Indication: Crohn's Disease

• Ligand: IL-6 receptor
• Indication: rheumatoid arthritis

• Ligand: p40 protein subunit of IL-12 and IL-23
• Indication: plaque psoriasis

• Ligand: IgE
• Indication: asthmas

• Ligand: respiratory syncytical virus
• Indication: prophylaxis against RSV infection

• Ligand: alpha 4 subunit of alpha-4-beta-1 and alpha-4-beta-7 integrins expressed on the surface of leukocytes
• Indication: multiple sclerosis

• Ligand: complement protein C5
• Indication: paroxysmal nocturnal hemoglobinuria (PNH)

• Ligand: CD11a, the alpha-subunit of leukocyte function antigen-1 (LFA-1)
• Indication: plaque psoriasis

• Ligand: IL-1beta
• Indication: Cryopyrin-associated Periodic Syndromes (CAPS)

• Ligand: RANKL (receptor activator of nuclear factor kappa B Ligand)
• Indication: bone, osteoporosis
• prevention of skeletal-related events in patients with bone metastases from solid tumors

• Ligand: TNF-alpha
• Indication: rheumatoid arthritis
• polyarticular-course juevenile rheumatoid arthritis
• ankylosing spnodylitis
• plaque psoriasis
• psoriatic arthritis

• Ligand: CD80 and CD86 (B7.1 and B7.2)
• Indication: rheumatoid arthritis

• Ligand: CD80 and CD86 (B7.1 and B7.2)
• Indication: renal transplantation

• Ligand: CD2 on T-lymphocytes
• Indication: plaque psoriasis

• Ligand: IL-1beta
• Indication: Cryopyrin-Associated Periodic Syndromes (CAPS)

• Ligand: VEGF
• Indication: neovascular ("wet") age-related macular degeneration (AMD)

• Ligand: CD33 on myeloid colony-forming cells
• Indication: acute myeloid leukemia (AML)